Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Ethics of Drug Discontinuation Studies in Schizophrenia

James D. Chandler, MD
Arch Gen Psychiatry. 1989;46(4):387. doi:10.1001/archpsyc.1989.0181004009320.
Text Size: A A A
Published online


To the Editor.—  I would like to register an ethical objection to the methodology used in the report by Lieberman et al1 regarding the prediction of relapse in schizophrenia. Briefly, their methods involved discontinuing antipsychotic medication in stable schizophrenics for up to one year and observing them for signs of relapse to judge the efficacy of a methylphenidate challenge in predicting relapse. While I would not have had any qualms about such a study in 1958, the situation is quite different in 1988. Few findings have been as well documented in medicine as the efficacy of antipsychotics in preventing relapse in schizophrenia.2,3 An investigator thus can be quite certain that discontinuing antipsychotics for up to a year will lead to relapse in most patients. This in fact was true in this study, in which only three of 39 patients did not relapse over a one-year period.One must


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.